Alcon News

1. Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia

   • Presbyopia is an eye condition that is part of natural aging affecting nearly 2 billion people worldwide.[1]
      
   • Dailies Total1® Multifocal contact lenses provide a seamless visual experience offering an alternative to bifocals or reading glasses.
      
   • They are designed to uniquely address end-of-day dryness and discomfort many contact lens wearers experience after age 40.[4]-[10]

   Basel, July 14, 2016 -Alcon, the global leader in eye care and a...

2. Addressing discomfort through contact lens innovation

   Graduate student Evan Sullivan switched to contact lenses, as they give him the freedom to enjoy his college lifestyle, work out at the gym and spend time on the beach without having to worry about his glasses while he is there.

   
   ...

3. Alcon receives European approval for new trifocal presbyopia-correcting intraocular lens for patients undergoing cataract surgery

   • Innovative AcrySof^® IQ PanOptix^®  trifocal intraocular lens design to improve near to intermediate vision andincrease independence from glasses
   • More than three million cataract surgeries performed in Europe annually[1]

   Basel, Switzerland, June 16, 2015 - Alcon, the global leader in eye care and a division of Novartis, has received European CE Mark for its AcrySof^® IQ PanOptix^®trifocal intraocular lens (IOL) for patients undergoing cataract surgery who elect to address their near...

4. Alcon Announces Acquisition of PowerVision, Inc.

   •  Acquisition demonstrates Alcon's commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who desire spectacle independence

   • US-based PowerVision, Inc. was formed to develop fluid-based accommodating intraocular lenses for cataract surgery patients
   • Fluid-based intraocular lens utilizes the eye's natural accommodative response to provide near and intermediate vision, in addition to distance vision...

5. Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress

   • Clareon^®intraocular lens (IOL) implanted with a unique single-use automated pre-loaded delivery system debuts with new data presentations
      
   • Congress program highlights Alcon's 70-year legacy of innovation including 100 million AcrySof^®IOL implants
      
   • New analyses show efficacy and safety of CyPass^® Micro-Stent in patients with glaucoma

   Basel, October 2, 2017 - Alcon, the global leader in eye care and a division of Novartis, will introduce Clareon^®, the...

6. Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting

   • Nearly 65% of eyes treated with personalized topography-guided LASIK experienced 20/16 vision or better[1] in clinical study
      
   • Alcon is the first refractive laser manufacturer to receive FDA approval for a topography-guided LASIK procedure  
      
   • Alcon to further showcase new data in glaucoma treatments, cataract as well as refractive surgery procedures using Wavelight technology

                
   Basel, November 15, 2015 -Alcon, the global leader in eye care and a division of...

7. Alcon receives FDA approval of new multifocal intraocular lens to treat cataract patients in the United States

   • US Food and Drug Administration (FDA) grants approval of the AcrySof^® IQ ReSTOR^® +2.5 Diopter (D) Intraocular Lens (IOL) for sale in the US  

   • Expands Alcon's IOL portfolio for the  correction of near, intermediate and distance vision in patients undergoing cataract surgery,with increased independence from glasses  

   • More than three million cataract surgeries are performed each year in the US

   Basel, Switzerland, April 16, 2015 - Alcon, the global leader in eye care and a...

8. Alcon receives FDA approval of Pazeo(TM) Solution for ocular allergy itch relief

   • US Food and Drug Administration grants approval of Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7% for sale in the United States

   • Developed with efficacy data at 24 hours, post dose, to provide one-drop daily ocular itch relief associated with allergic conjunctivitis (eye allergies)

   • Up to 30% of the U.S. population is affected by seasonal allergy symptoms, with as many as 70 to 80% of these demonstrating ocular symptoms such as itching[1]

   Basel, February 2, 2015 - Alcon, the global...